[Clinical analysis of reactive XXXX following chemotherapy for childhood @entity706 ].

@entity1 @entity706 @entity5 @entity8792 @entity1893 @entity978
BACKGROUND _ OBJECTIVE: Reactive @entity8792 following chemotherapy for @entity5 is likely to be misdiagnosed as @entity5 residue or relapse, therefore, leads to unnecessary treatment. This study was to analyze the clinical features of reactive @entity8792 following chemotherapy for childhood @entity706 . METHODS: Clinical data of 13 @entity1 with reactive @entity8792 following chemotherapy for @entity706 , treated from Mar. 1999 to Mar. 2004, were retrospectively analyzed. Of the 13 cases, 5 were @entity978 ( @entity978 ), and 8 were @entity1893 ( @entity1893 ). All @entity1 received computed tomography (CT) to evaluate the therapeutic effect. When a new thymic mass emerged, positive electron tomography/computed tomography (PET/CT) was performed to identify its quality. RESULTS: At diagnosis, 10 @entity1 had mediastinal involvement. Reactive @entity8792 occurred following the completion of chemotherapy in 9 cases, or during the maintenance of chemotherapy in 4 cases. CT showed that the longest diameters of the new mediastinal masses were 2.2-6.0 cm (mean 3.7 cm). The interval from last chemotherapy cycle to the occurrence of @entity8792 was 2-12 months (mean 4 months). PET/CT was performed to 5 cases, and showed no vital @entity5 in the mediastinum. Three cases were misdiagnosed as @entity5 residue or relapse, and received second-line therapy. All @entity1 were followed-up for 1-6 years (median 4 years), and none @entity5 relapse. CONCLUSIONS: Reactive @entity8792 may occur following intensive chemotherapy for childhood @entity706 . It should not be misdiagnosed as @entity5 and overtreated.
